WILMINGTON, Del--Zeneca Pharmaceuticals has received clearance from the FDA to market a new formulation of Zoladex (goserelin acetate implant) for the palliative treatment of advanced prostate cancer.
WILMINGTON, Del--Zeneca Pharmaceuticals has received clearancefrom the FDA to market a new formulation of Zoladex (goserelinacetate implant) for the palliative treatment of advanced prostatecancer.
The new formulation, a 10.8-mg goserelin acetate implant givenevery 3 months, offers greater convenience to patients choosingtreatment with a luteinizing-hormone-releasing hormone (LHRH)analog, the company said.
The original 1-month 3.6-mg formulation of Zoladex implants hasbeen available in the United States since 1989 for the treatmentof advanced prostate cancer. The drug has been marketed since1993 for the treatment of endometriosis, and it was recently clearedby the FDA for the treatment of advanced breast cancer in premenopausaland perimeno-pausal women.
Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology
September 20th 2022Authors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.
Data Support Early Genetic Testing in HRR+ mCRPC Managed With Olaparib
January 27th 2024Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.